Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million

The determination marks Ipsen’s 2nd acquisition this week aft its statement to instrumentality implicit Kartos Therapeutics, a institution processing a cause to dainty a uncommon humor cancer.